ライフサイエンスコーパス: extrahepatic

1 the site of insulin action to control EGP is extrahepatic.

2 onths; extrahepatic: 16.6 months; intra- and extrahepatic: 16.2 month; P > 0.05).

3 te of recurrence (intrahepatic: 16.9 months; extrahepatic: 16.6 months; intra- and extrahepatic: 16.2

4 3.2%), extrahepatic only (35.8%), intra- and extrahepatic (21.0%).

5 ography in the detection and localization of extrahepatic (99m)Tc-MAA and to evaluate the typical and

6 All images were reviewed for hepatic and extrahepatic (99m)Tc-MAA deposition and compared with th

7 estimate the liver-to-lung shunt and exclude extrahepatic (99m)Tc-MAA deposition.

8 The extrahepatic activity was measured as the sum of all vox

9 on, new hepatic lesions) progression or (ii) extrahepatic (adrenal/bone/lung/lymph node) metastases.

10 C finding on ERCP is involvement of both the extrahepatic and intrahepatic bile ducts, with small duc

11 holangiopathy that culminates in fibrosis of extrahepatic and intrahepatic bile ducts.

12 flammatory disorder of infants involving the extrahepatic and intrahepatic biliary tree.

13 ells, are found in peribiliary glands within extrahepatic and large intrahepatic bile ducts.

14 buted relatively equally among intrahepatic, extrahepatic, and intra- plus extrahepatic sites.

15 Here, we identify extrahepatic arginase-1(+) Id2(+) fetal ILC precursors t

16 cificity of (99m)Tc-MAA SPECT when detecting extrahepatic arterial shunting.

17 median age 58 years; median AMA titer 1:160; extrahepatic autoimmune disorders 46%; normal serum alka

18 HCV) infection is frequently associated with extrahepatic autoimmune disorders while interferon (IFN)

19 gkin lymphoma (P < .001) and gallbladder and extrahepatic bile duct cancer (P = .01) was observed.

20 higher: 100% for gallbladder cancer, 97% of extrahepatic bile duct cancer, 91% of ampula of Vater ca

21 ered or partially covered) for palliation of extrahepatic bile duct obstruction initially is more exp

22 doscopic stents are placed for palliation of extrahepatic bile duct obstruction.

23 ed by lymphadenectomy (67%) and sometimes by extrahepatic bile duct resection (23%).

24 Extrahepatic bile duct resection with hepaticoenterostom

25 h biliary tract cancer (237 gallbladder, 127 extrahepatic bile duct, and 47 ampulla of Vater), 895 wi

26 ls residing in the submucosal compartment of extrahepatic bile ducts (EHBDs).

27 e livers and were the most abundant cells in extrahepatic bile ducts at the time of obstruction.

28 and active caspase-3 staining in livers and extrahepatic bile ducts from Balb/c mice infected with R

29 flammatory cholangiopathy that obstructs the extrahepatic bile ducts in young infants.

30 f cancers that arise in either the intra- or extrahepatic bile ducts or the gallbladder.

31 progressive fibroinflammatory obstruction of extrahepatic bile ducts that presents as neonatal choles

32 d cholangiocytes, that line intrahepatic and extrahepatic bile ducts, contribute substantially to bil

33 truction of segments or the entire length of extrahepatic bile ducts, the timely pursuit of hepatopor

34 epithelial and subepithelial compartments of extrahepatic bile ducts, with onset within 3 days and pe

35 sulting in dramatic and rapid enlargement of extrahepatic bile ducts.

36 pithelial malignant neoplasm of the liver or extrahepatic bile ducts.

37 mechanistically linked to obstruction of the extrahepatic bile ducts.

38 flammation and fibrosis of the intra- and/or extrahepatic bile ducts.

39 Sar among blood, hepatocytes, and intra- and extrahepatic bile ducts.

40 h affect these loops and are associated with extrahepatic biliary atresia, lead to a loss of membrane

41 tire glandular stomach, rostral duodenum and extrahepatic biliary system to pancreas, with formation

42 resulting in inflammatory obstruction of the extrahepatic biliary tract and intrahepatic bile ducts.

43 that PBGs populate the entire length of the extrahepatic biliary tract, except the gallbladder.

44 at the upper, middle, and lower part of the extrahepatic biliary tree in 11, 4, and 4 patients (58%,

45 A) is a fibroinflammatory obstruction of the extrahepatic biliary tree in neonates.

46 propagation of human cholangiocytes from the extrahepatic biliary tree in the form of extrahepatic ch

47 Associated resection of the extrahepatic biliary tree was required in 11 cases (58%)

48 ul imaging modality for the pancreas and the extrahepatic biliary tree.

49 enitors are present in peribiliary glands of extrahepatic biliary trees from humans of all ages and i

50 ptoms of HCC and/or vascular invasion and/or extrahepatic cancer are considered to have advanced-stag

51 ses in 48 (47%; bacterial infection: n = 13; extrahepatic cancers: n = 10; cardiovascular events: n =

52 r cancer: n = 18; miscellaneous, n = 30) and extrahepatic causes in 48 (47%; bacterial infection: n =

53 stigated the relative role of hepatic versus extrahepatic CB1 receptors in the metabolic consequences

54 ies where the distinction between intra- and extrahepatic CC was used, some potential risk factors se

55 y its subtypes; intrahepatic CCA (iCCA), and extrahepatic CCA (eCCA).

56 e present in the preponderance of intra- and extrahepatic CCA specimens.

57 50 human CCA samples (25 intrahepatic and 25 extrahepatic CCA) as well as human KMCH-1, Mz-CHA-1, and

58 We profiled 10 intrahepatic and 8 extrahepatic CCs in comparison to non-neoplastic biliary

59 We conclude: (1) extrahepatic cells can differentiate into liver tissues;

60 nclude endocrine effects, HCV replication in extrahepatic cells, or a heightened immune reaction with

61 e measured in the following intrahepatic and extrahepatic cholangiocarcinoma (CCA) cell lines, Mz-ChA

62 known about the association between HCV and extrahepatic cholangiocarcinoma (ECC) or pancreatic canc

63 The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder ca

64 as intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma.

65 = 3, intrahepatic cholangiocarcinoma: n = 2, extrahepatic cholangiocarcinoma: n = 2, malignant epithe

66 ct cancers (BTC), which encompass intra- and extrahepatic cholangiocarcinomas and gallbladder carcino

67 t cancers (BTCs), which encompass intra- and extrahepatic cholangiocarcinomas as well as gallbladder

68 the extrahepatic biliary tree in the form of extrahepatic cholangiocyte organoids (ECOs) for regenera

69 Biliatresone has selective toxicity for extrahepatic cholangiocytes (EHCs) in zebrafish larvae.

70 s probably multifactorial, with obliterative extrahepatic cholangiopathy as the common endpoint.

71 testinal FXR protected mice from obstructive extrahepatic cholestasis after bile duct ligation or adm

72 During extrahepatic cholestasis and other pathologic conditions

73 intestinal FXR in mice with intrahepatic and extrahepatic cholestasis.

74 nt model of insulin kinetics and hepatic and extrahepatic clearance parameters were estimated.

75 (n = 27) or absence (n = 14) of significant extrahepatic comorbidities.

76 ajor clinical problem that leads to frequent extrahepatic complications including intestinal dysfunct

77 to develop a frailty index to capture these extrahepatic complications of cirrhosis and enhance mort

78 Metabolic Bone disorders are well-recognized extrahepatic complications of cirrhosis.

79 tion and to reduce the burden of hepatic and extrahepatic complications of HCV that are observed in k

80 oma, and end-stage liver disease, as well as extrahepatic complications such as cryoglobulinemia and

81 s associated with hemorrhagic and thrombotic extrahepatic complications.

82 normal kidney function or do not have severe extrahepatic conditions, TIPS is an excellent option to

83 ic cytochrome b(5) deletion, suggesting that extrahepatic cytochrome b(5) plays a significant role in

84 ults demonstrate that hepatic and, possibly, extrahepatic cytochrome P450 (P450) enzymes play a role

85 titis C virus (HCV) infection on hepatic and extrahepatic deaths.

86 Extrahepatic deposition of a (166)Ho scout dose seems to

87 r, in contrast to (99m)Tc-MAA, an unintended extrahepatic deposition of this beta-emitting scout dose

88 Of 160 patients, 32 patients (34 cases) of extrahepatic deposition were identified.

89 used for lung shunt analysis, evaluation of extrahepatic deposition, and sometimes for treatment pla

90 Of the extrahepatic depositions of (99m)Tc-MAA on SPECT, the am

91 e (2.4), tumor burden (2.8), and presence of extrahepatic disease (3.5).

92 (P = .003), high modified CRS (P = .02), and extrahepatic disease (EHD) (P < .001).

93 ectal liver metastases (CRLM) and concurrent extrahepatic disease (EHD), and to define prognostic fac

94 ectal liver metastases (CRLM) and concurrent extrahepatic disease (EHD), and to define prognostic fac

95 Patients with extrahepatic disease and positive lymph node primary tum

96 correlated with the severity of hepatic and extrahepatic disease and systemic inflammatory responses

97 astases identified patients with concomitant extrahepatic disease as a group with poor outcomes.

98 onous presentation, primary node status, and extrahepatic disease as matching variables to compare ov

99 isease (range, 0 to 5 regimens), and 45% had extrahepatic disease at study entry.

100 Extrahepatic disease localization is reconfirmed not to

101 These studies concluded that the presence of extrahepatic disease should be a contraindication to res

102 al after resection is worse in patients with extrahepatic disease than in patients with liver-only di

103 Extrahepatic disease was present at time of LT in 4 (19%

104 lar thrombosis (TVT) was present in 55%, and extrahepatic disease was present in 12%.

105 , absence of postoperative chemotherapy, and extrahepatic disease were predictive of recurrence (HR=2

106 ighly selected patients with single sites of extrahepatic disease, although expectations should be di

107 performance status, macrovascular invasion, extrahepatic disease, and alpha-fetoprotein level to bes

108 or B, ECOG performance status of 0 to 2, no extrahepatic disease, and no prior radiation received 15

109 or and metastases, CRLM number and diameter, extrahepatic disease, and preoperative chemotherapy.

110 olization, hepatic tumor burden, presence of extrahepatic disease, and sex.

111 nvasion (HR = 2.2; P = 0.03), but not pre-LT extrahepatic disease, were significant risk factors for

112 had 4 or more CRLM, and 22.5% had associated extrahepatic disease.

113 lly appraise key studies on NAFLD-associated extrahepatic disease.

114 evaluation because of accurate assessment of extrahepatic disease.

115 for patients with resectable tumors without extrahepatic disease.

116 tients with liver metastases and concomitant extrahepatic disease.

117 ted for resection of hepatic metastases with extrahepatic disease.

118 e than 3 liver metastases, R1 resection, and extrahepatic disease.

119 AFLD may be a new, and added risk factor for extrahepatic diseases such as CVD, chronic kidney diseas

120 nificantly higher mortality from hepatic and extrahepatic diseases than anti-HCV seropositives with u

121 s had higher mortality from both hepatic and extrahepatic diseases, showing multivariate-adjusted haz

122 ) for hepatic diseases; 1.35 (1.15-1.57) for extrahepatic diseases; 1.50 (1.10-2.03) for circulatory

123 otential of targeting KC for immune-mediated extrahepatic disorders.

124 Extrahepatic distributions included lungs (100%), the ga

125 s, with type 3 being the most common type of extrahepatic duct involvement and detected in 16 (35.5%)

126 Livers and remnant extrahepatic ducts from BA patients were evaluated by qu

127 were involved in 11 (24.4%) patients and the extrahepatic ducts were involved in 14 (31.1%), with 17

128 In children with BA, both intra- and extrahepatic ductular cells demonstrated striking up-reg

129 The mechanisms causing the extrahepatic effects of HCV infection are likely multifa

130 s of insulin on HGP and utilization, and (2) extrahepatic effects of insulin are sufficient to mainta

131 ribavirin was shown to improve some of these extrahepatic effects; sustained virological response is

132 After 3 years of follow-up, extrahepatic events still explained half of deaths in pa

133 FT505 concentrated in the liver with limited extrahepatic exposure and underwent extensive enterohepa

134 7 cm), and solitary (ISS) and those that had extrahepatic extension and were large (>/=7 cm) and mult

135 Lack of hepatic preconditioning, extrahepatic extension of resection, and postoperative c

136 zards model demonstrated that multifocality, extrahepatic extension, grade, node positivity, and age

137 ithout metastatic disease, nodal metastasis, extrahepatic extension, or major vascular invasion).

138 The latter would be the definite proof of extrahepatic, extrarenal glucose production.

139 However, higher ELF scores may reflect extrahepatic fibrosis in HIV-infected patients with a hi

140 It is provocative to speculate that extrahepatic HCV diversity may be an important determina

141 Interestingly, hepatic and extrahepatic Hh-pathway was enhanced in PPVL rats, which

142 s in vivo would improve graft function at an extrahepatic implantation site.

143 to the liver in 1 patient (4%), exclusively extrahepatic in 18 patients (72%), and were both intra a

144 n 18 patients (72%), and were both intra and extrahepatic in 6 patients (24%).

145 ssion pattern was divided into: intrahepatic/extrahepatic increase in tumor size, new intrahepatic le

146 ype 2 diabetes by altering either hepatic or extrahepatic insulin action.

147 ce test (FSIGT), we estimated hepatic versus extrahepatic insulin clearance in 29 EA and 18 AA health

148 el-based method to estimate both hepatic and extrahepatic insulin clearance using plasma insulin and

149 epatic extraction was 25.8% [32.7%], and for extrahepatic insulin clearance was 20.7 mL/kg/min [11.7

150 In contrast, extrahepatic insulin clearance was not lower in AAs than

151 cterizes the contributions of hepatic versus extrahepatic insulin degradation related to ethnic diffe

152 Hepatic and extrahepatic insulin resistance contribute to fasting hy

153 ic insulin sensitivity; sitagliptin enhanced extrahepatic insulin sensitivity with a synergistic effe

154 trapancreatic bile duct in 51%; the proximal extrahepatic/intrahepatic ducts were involved in 49%.

155 The presence of proximal extrahepatic/intrahepatic strictures was predictive of r

156 din insufficiency, hepatic iron loading, and extrahepatic iron accumulation in males.

157 g, representing an environment favorable for extrahepatic iron deposition.

158 tain hepcidin to a level sufficient to avoid extrahepatic iron loading.

159 tumor size, new intrahepatic lesion, and new extrahepatic lesion (NEH).

160 PET/CT showed uptake in 18 extrahepatic lesions and no uptake in 3 lesions affirmed

161 f the different imaging modalities to detect extrahepatic MAA shunting was compared.

162 umor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic

163 ents at risk for HCC but without established extrahepatic malignancy from August 2012 through August

164 The risk of hepatic and extrahepatic malignancy was significantly increased in A

165 2.9), and 5.2 (95% CI 3.3-7.8), and SIRs for extrahepatic malignancy were 2.7 (95% CI 1.8-3.9), 1.6 (

166 xed cryoglobulinemia (MC) is the most common extrahepatic manifestation of chronic hepatitis C virus

167 h clinical data, this description of a novel extrahepatic manifestation of NASH should sensitize derm

168 lomerulonephritis seems to be an HEV-related extrahepatic manifestation.

169 is the burden of HCV disease associated with extrahepatic manifestations (diabetes, B-cell proliferat

170 Few data regarding genotype 3 HEV extrahepatic manifestations exist.

171 meta-analysis to determine the prevalence of extrahepatic manifestations in patients with HCV infecti

172 However, important extrahepatic manifestations include immune complex glome

173 Extrahepatic manifestations of HBV infection are rare bu

174 h condition to determine prevalence rates of extrahepatic manifestations of HCV infection and their e

175 Total direct medical costs of extrahepatic manifestations of HCV infection, in 2014 US

176 prevalence, risks, and costs associated with extrahepatic manifestations of HCV infection.

177 t, outpatient, and pharmacy) associated with extrahepatic manifestations of HCV infection.

178 r 2014, to identify studies of the following extrahepatic manifestations of HCV infection: mixed cryo

179 ic conditions associated with HCV infection, extrahepatic manifestations of HCV may become a major in

180 likely result in greater improvements in the extrahepatic manifestations of HCV.

181 a from 102 studies, we found the most common extrahepatic manifestations to be diabetes (in 15% of pa

182 itis C virus (HCV) infection has hepatic and extrahepatic manifestations with various costs and impai

183 In addition, these mice exhibit extrahepatic manifestations, including pancreatic cysts,

184 s (HCV) infection is associated with several extrahepatic manifestations.

185 nce of signaling pathways and involvement of extrahepatic mediators like adiponectin.

186 To understand the role of hepatic vs extrahepatic metabolism in the disposition of chiral PCB

187 ents followed until death, only 50 developed extrahepatic metastases (24%).

188 The presence of extrahepatic metastases (mean survival in both groups, 4

189 01), macrovascular invasion (P < 0.001), and extrahepatic metastases (P < 0.002).

190 OC PET/CT detected additional hepatic and/or extrahepatic metastases in 22 of the 33 patients diagnos

191 LSF did not correlate with the presence of extrahepatic metastases or prior administration of bevac

192 Histologic examination demonstrated that no extrahepatic metastases were detectable during primary t

193 with liver metastases plus or minus limited extrahepatic metastases were randomly assigned to receiv

194 extrahepatic macroscopic vascular invasion, extrahepatic metastases).

195 ce status, no more than 25% tumor burden, no extrahepatic metastases, albumin greater than 3 g/dL, an

196 ts in the absence of macrovascular invasion, extrahepatic metastases, and deteriorated PS predicts th

197 Covariates of age, sex, preexisting extrahepatic metastases, liver enzyme levels, tumor volu

198 ocoregional therapies die without developing extrahepatic metastases, the notion of HCC as a systemic

199 minimisation with four factors: presence of extrahepatic metastases, tumour involvement of the liver

200 % of patients with HCC in NCL presented with extrahepatic metastases.

201 ognosis as a result of widespread intra- and extrahepatic metastases.

202 ration reduced MMP7 messenger RNA levels and extrahepatic metastases.

203 tastases and possibly delayed progression of extrahepatic metastases.

204 l, and does not correlate to the presence of extrahepatic metastases.

205 Furthermore, LOXL2 facilitated extrahepatic metastasis by enhancing recruitment of bone

206 tus of 1-2, and/or macrovascular invasion or extrahepatic metastasis) were included in the study (n =

207 ence in clinical outcome between hepatic and extrahepatic metastatic disease.

208 Mice with loss-of-function mutation in the extrahepatic mitochondrial enzyme CoA transferase (succi

209 Cytochrome P450 (CYP) 1A1 is an extrahepatic monooxygenase involved in the metabolism of

210 the main factor associated with hepatic and extrahepatic nADEs in HIV controllers.

211 Intra- and extrahepatic NK-cell subsets from HCV-infected patients

212 Extrahepatic nonmalignant partial PVT improved spontaneo

213 cutive patients with cirrhosis and untreated extrahepatic, nonmalignant partial PVT were followed up

214 currence site was intrahepatic only (43.2%), extrahepatic only (35.8%), intra- and extrahepatic (21.0

215 termine the mechanisms of hepatic IR-induced extrahepatic organ dysfunction.

216 ays a critical role in hepatic IR injury and extrahepatic organ dysfunction.

217 ACLF was defined as two or more extrahepatic organ failures in patients with cirrhosis.

218 isting chronic liver disease and hepatic and extrahepatic organ failures, and is associated with subs

219 ay survival worsened with a higher number of extrahepatic organ failures, none (92%), one (72.6%), tw

220 mber of liver segments resected, concomitant extrahepatic organ resection, a diagnosis of primary liv

221 e likely to reflect epithelial cell death in extrahepatic organs.

222 CYP2S1 and CYP2W1, two extrahepatic P450 enzymes identified from the human geno

223 f (90)Y-microspheres to the lungs; to detect extrahepatic perfusion emerging from the injected vascul

224 most common being the presence of intra- or extrahepatic portal abnormalities.

225 tosis-mediated islet death within portal and extrahepatic portal sites in mice.

226 ding indications for MesoRex bypass (MRB) in extrahepatic portal vein obstruction and the role of pri

227 Therefore, children with extrahepatic portal vein obstruction should be offered M

228 The vast majority of children with extrahepatic portal vein obstruction will experience com

229 ly more frequently in OPV than in cirrhosis: extrahepatic portal vein thrombosis (18 [43%] of 42 vs f

230 etric features of the liver in children with extrahepatic portal vein thrombosis (EHPVT), with surgic

231 Two patients had an extrahepatic portosystemic shunt, 17 had a portacaval sh

232 All extrahepatic portosystemic shunts, H-type portal-caval,

233 95% CI: 1.544-2.975; P < 0.001), concomitant extrahepatic procedures (HR: 1.742, 95% CI: 1.103-2.750;

234 oss of ketone body oxidation, an exclusively extrahepatic process, disrupts hepatic intermediary meta

235 treated with exogenous PP-IX (mimicking XLP extrahepatic protoporphyria) or with the iron chelator d

236 37.7%) patients having both intrahepatic and extrahepatic PSC.

237 event involving coordinated intrahepatic and extrahepatic regulation.

238 nsmitted infection that has both hepatic and extrahepatic repercussions.

239 CRBP1, and CD36 in retinoid mobilization and extrahepatic retinoid uptake, as well as a role for CYP2

240 retinoid dehydrogenase mRNAs and activities, extrahepatic retinol concentrations, and atRA catabolism

241 Extrahepatic SAA was detected locally in COPD bronchoalv

242 lective internal radiation therapy to detect extrahepatic shunting to the lung or the gastrointestina

243 me verification of delivery and detection of extrahepatic shunting.

244 he different hepatic cell types and multiple extrahepatic signals.

245 imal site for islet transplantation, several extrahepatic sites have been studied.

246 is the first report on the identification of extrahepatic sites of HEV replication in animals after e

247 PCR (RT-PCR) assay for the identification of extrahepatic sites of HEV replication.

248 Several extrahepatic sites were tested in experimental animals,

249 in amino acid metabolism in the liver and at extrahepatic sites.

250 intrahepatic, extrahepatic, and intra- plus extrahepatic sites.

251 oenvironments that promote graft efficacy at extrahepatic sites.

252 with prolonged progression-free survival in extrahepatic sites.

253 core (ECOG PS; 0 or 1), vascular invasion or extrahepatic spread (yes or no), and hepatitis B virus (

254 S 0, 65.2%; HBV, 49.1%; vascular invasion or extrahepatic spread, 70.1%).

255 The extrahepatic stem cell niches are the peribiliary glands

256 itions, indication and extent of hepatic (or extrahepatic) surgery and the hospital type, location, a

257 disease and is associated with a variety of extrahepatic syndromes, including central nervous system

258 But extrahepatic synthesis also occurs, and mounting evidenc

259 rculating complement protein synthesis site, extrahepatic synthesis is known to optimize local tissue

260 ression-free survival (PFS) in the liver and extrahepatic (systemic) organs were retrospectively eval

261 is whether procarcinogen bioactivation in an extrahepatic target tissue (e.g., the lung) is essential

262 the targeting ligand, have the potential for extrahepatic targeting.

263 CD8(+) T cells generated by infection at an extrahepatic, that is, subcutaneous, site.

264 othyroidism-induced NAFLD is both intra- and extrahepatic; they also reveal key metabolic differences

265 expression, Bmp/Smad signaling, hepatic and extrahepatic tissue iron accumulation) with that of sing

266 ontent was mobilized from the liver, causing extrahepatic tissue retinoid levels to increase.

267 f Foxo1, insulin signals via an intermediary extrahepatic tissue to regulate liver glucose production

268 t the poor distribution of PA-based drugs to extrahepatic tissues and thereby to improve the therapeu

269 de novo lipogenesis, whereas its actions on extrahepatic tissues are mediated by IGF-1.

270 The characterization of VKOR activity in extrahepatic tissues demonstrated that a part of the VKO

271 ining the supply of energy from the liver to extrahepatic tissues during periods of prolonged food de

272 Of 29 different extrahepatic tissues evaluated by real-time polymerase c

273 by an initial phase of rapid mobilization to extrahepatic tissues followed by extensive catabolism wi

274 iched plasma HDL may serve to deliver S1P to extrahepatic tissues for atheroprotection and may have o

275 Circulating retinol may be taken up by extrahepatic tissues or recycled back to liver multiple

276 the vitamin K-dependent protein produced by extrahepatic tissues such as matrix Gla protein or osteo

277 studies indicated that As3MT is required in extrahepatic tissues to promote atherosclerosis.

278 aling molecules that act at both hepatic and extrahepatic tissues to regulate lipid and carbohydrate

279 rtly explains the low susceptibility of some extrahepatic tissues to vitamin K antagonists and the la

280 1) and secretes it into the plasma to supply extrahepatic tissues with selenium.

281 (RBP4) transports retinol from the liver to extrahepatic tissues, and RBP4 lowering is reported to i

282 In extrahepatic tissues, MondoA, the paralog of ChREBP, par

283 In extrahepatic tissues, some changes in P450 expression we

284 ved in the breakdown of ketone bodies in the extrahepatic tissues, was identified in rat heart to und

285 more recently explored functions of PCSK9 in extrahepatic tissues.

286 unctions of cytochrome b(5), particularly in extrahepatic tissues.

287 gene but retain normal expression of Igf1 in extrahepatic tissues.

288 ability thereby minimizing distribution into extrahepatic tissues; concurrently, they were also optim

289 eloping a clinically applicable protocol for extrahepatic transplantation of pancreatic islets.

290 A retrievable, extrahepatic transplantation site that mimics the pancre

291 pendently predicted by PS, prothrombin time, extrahepatic tumor spread, macrovascular invasion, and r

292 macroscopic vascular invasion, and 38% with extrahepatic tumor spread.

293 can readily be extended to a broad range of extrahepatic tumors, transgenic tumors with defined mech

294 ns (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spon

295 The hepatic UGTs 2B17 and 1A9 and the extrahepatic UGTs 1A8 and 1A10 exhibited the highest ove

296 For variants of active extrahepatic UGTs, the UGT1A8(173Ala/277Tyr) variant exh

297 ions for the assessment of lung shunting and extrahepatic uptake.

298 The energy-intense nature of hepatic and extrahepatic urea osmolyte production for renal water co

299 the imbalance between hepatic production and extrahepatic utilization of ketone bodies.

300 ahepatic vascular invasion), and presence of extrahepatic vascular invasion or metastasis were includ